Get started
CRISPR THERAPEUTICS AGCRISPR THERAPEUTICS AGCRISPR THERAPEUTICS AG

CRISPR THERAPEUTICS AG

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

CRSP/N trade ideas

CRSP: Due Diligence & Roadmap***Scroll along the chart to see this years key data*** About Crispr Therapeutics CRISPR Therapeutics AG is a gene editing company focused on the development of CRISPR/Cas9- based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. It aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. They currently lead programs targeting the blood diseases beta-thalassemia and sickle cell disease has entered clinical testing, as has our first allogeneic CAR-T program targeting B-cell malignancies. What is CRISPR/Cas-9? Diseases such as cancer, diabetes, down syndrome, and Huntington's disease are the consequence of abnormal proteins that exist because of mutations in specific genes in a patients DNA. These mutations are specific sequences of genomic DNA. CRISPR/Cas-9 is a novel gene editing system that may allow us to modify, correct, or delete specific areas, or sequences, within a patients DNA, allowing us to treat these diseases. CRISPR is comprises of Cas-9; an enzyme that cuts DNA, and a guide RNA whose sequence directs Cas-9 to a specific location within the DNA where the edit should be made. The gene editing process begins when the complex recognizes a specific sequence of DNA and binds to the short segment. This initiates unwinding of the double helix which causes the guide RNA to pair with a specific target sequence within the DNA. Once paired precisely with the desired sequence, Cas-9 cuts out the DNA causing a strand break. Disruption is when the DNA sequence is broken and reconnects, causing inactivation along a specific sequence. Deletion is when two different guide RNAs target separate sites on either side of the desired deletion and the repair process joins the separate ends, deleting the intervening sequence. Corrections can be made by adding a DNA template along with a Cas-9/guide-RNA complex, the template includes DNA sequences that exactly match the DNA sequences adjacent to the target cut site, through a naturally occurring process the correction template is added to the desired break to repair the sequence, thus inserting a new gene. Pipeline Hemoglobinopathies CTX001; Clinical: Autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy in development for patients suffering from beta-thalassemia and sickle cell disease Immuno-Oncology CTX110; Clinical: Allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy targeting CD19 in development for the treatment of CD19+ malignancies CTX120; Clinical: Allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy targeting BCMA in development for the treatment of multiple myeloma CTX130; Clinical: Allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy targeting CD70 in development for the treatment of both solid tumors and hematologic malignancie Regenerative Medicine Type I diabetes mellitus; IND-enabling: Allogeneic beta-cell replacement therapy derived from a CRISPR/Cas9 gene-edited immune-evasive stem cell line in development for the treatment of diabetes In Vivo Approaches Glycogen storage disease type la (GSD la) Duchenne muscular dystrophy (DMD) Myotonic dystrophy type 1 (DM1 ) Cystic fibrosis (CF) *all in Research phase Programs: Hemoglobinopathies About: The inherited hemoglobinopathies beta-thalassemia and sickle cell disease (SCD) result from mutations in a gene that encodes a key component of hemoglobin, the oxygen carrying molecule in blood. Both diseases currently require lifetime treatment that can result in the need for regular transfusions, painful symptoms and chronic hospitalizations. Both of these diseases result in reduced life expectancy. CRISPR program: As a therapy, CTX001 involves isolating a patient’s own blood stem cells, editing them with CRISPR/Cas9 to increase HbF expression, and then returning the edited cells to the patient. We believe that over time these edited blood stem cells will generate red blood cells that have increased levels of HbF, which may reduce or eliminate patients’ symptoms. In 2017, we signed an agreement to co-develop and co-commercialize this program with our partner Vertex Pharmaceuticals. Immuno-Oncology About: Over the past several decades, scientists have sought to engineer immune cells to seek and destroy cancer cells. These efforts eventually led to the approval by the FDA of two chimeric antigen receptor (CAR) T cell therapies in 2017. CRISPR program: For our initial allogeneic gene-edited CAR-T product candidates, such as our lead immuno-oncology program CTX110, we make three modifications to healthy donor T cells to allow our CAR-T cells to be used off-the-shelf: - CAR: The chimeric antigen receptor (CAR) allows CAR-T cells to target and kill cancer cells. We use CRISPR/Cas9 to insert the CAR construct precisely into the TCR alpha constant (TRAC) locus, which we expect to result in a safer, more consistent product. - TCR: T cells use the T cell receptor (TCR) to recognize and kill cells presenting foreign antigens (a sign of infection), thereby providing immunity from disease. We use CRISPR/Cas9 to eliminate the TCR with high efficiency, which reduces the risk of GvHD occurring during off-the-shelf use. - MHC I: To improve CAR-T cell persistence and increase the chance for durable remissions, we use CRISPR/Cas9 to eliminate the class I major histocompatibility complex (MHC I) expressed on the surface of our CAR-T product candidates. Regenerative Medicine About: Regenerative medicine, or the use of stem cells to repair or replace tissue or organ function lost due to disease, damage or age, holds tremendous potential in both rare and common diseases. The field is rapidly approaching the point where compelling clinical proofs of concept will likely begin to emerge. Most of these efforts use unmodified stem cells, and the potential to genetically engineer these cells via gene editing is tremendous. We are pursuing gene-editing approaches to allow allogeneic use of stem cell-derived therapies by enabling immune evasion, improving existing cell function and directing cell fate using CRISPR/Cas9. CRISPR program: Our gene-editing technology offers the potential to protect the transplanted cells from the patient’s immune system by ex vivo editing immune-modulatory genes within the stem cell line used to produce the pancreatic-lineage cells. The speed, specificity and multiplexing efficiency of CRISPR/Cas9 make our technology ideally suited to this task. We have established significant expertise in immune-evasive gene editing through our allogeneic CAR-T programs. The combination of ViaCyte’s stem cell capabilities and our gene-editing capabilities has the potential to enable a beta-cell replacement product that may deliver durable benefit to patients without triggering an immune reaction. In Vivo Approaches About: Currently, several methods exist to deliver DNA or RNA to cells inside the body, which we can adapt to deliver CRISPR/Cas9 components. These methods fall into two broad categories: viral and non-viral. We are developing therapeutic programs based on technologies in both these areas. - Viral: For organ systems, including the muscle, lung and central nervous system, we have emphasized viral delivery, primarily using adeno-associated viral (AAV) vectors. These vectors can deliver DNA encoding for Cas9 and guide RNAs into specific tissues of the body. - Non-viral: Our efforts into non-viral delivery methods have focused on lipid nanoparticles (LNPs), which predominantly target the liver. We can encapsulate messenger RNA (mRNA) encoding Cas9 and guide RNA, and a donor DNA template if necessary, into LNPs to shuttle these components to the liver. Key Financials: Balance sheet: (06/30/2020) ($Mil) Cash assets: 945.1 Current liabilities: 74.5 Long-term debt: 0 Income statement: ($Mil) Revenue: 2016: 5.164 2017: 40.997 2018: 3.124 2019: 289.59 Operating income: 2016: (56.648) 2017: (64.648) 2018: (158.943) 2019: 46.74 Financial health: Strong (87/100) Institutional decisions: 4Q19: - To buy: 155 - To sell: 71 1Q20: - To buy: 141 - To sell: 99 2Q20: - To buy: 148 - To sell: 102 Street consensus: 2.39/Buy I didn't include too much financial data because the company is still in its research/growth phase (think Apple in the early 2000s). I am long-term bullish on Crispr because I believe genomics along with their therapeutics are the future of medicine for serious human diseases. CRISPR system is one of the most powerful scientific breakthroughs of the decade and we are still yet to see its full potential. The possibilities of gene editing are endless and I can't wait to see the next 10 years of progress within the field of genomics This post took me hours to create, I'd appreciate a thumbs up! :)
NASDAQ:CRSP
by RaftoO
16
CRSP - Bull PennantCRSP was on a roll since it broke out of consolidation range (>112) on Nov 27. It started to form a bull pennant for the past week giving late comers an opportunity to stake. There are 2 possible entries we can consider. The traditional way is to enter upon the break up of the bull pennant (this way the trade will almost always go our way). However, I do not mind entering at the lower end of the pennant (could mean longer wait before we see a good move). Either way, I would still place a stop loss abt $1 below the pennant low of 138. Trail it upwards once we have a reasonable profit. We do not know how high it can go eventually hence trail your stops upward (giving enough room to swing) or take partial profits along the way up.
NASDAQ:CRSPLong
by Juliac
Stock to watch: Crispr Therapeutics AG (CRSP) - re-uploadNASDAQ:CRSP Re-uploading the original idea from Nov 24 (which was brutally deleted by the moderators LOL) 👇🏻 Original chart from Nov 24 May be an interesting stock to trade: Buy/Sell Zones indicates a 20-day uptrend. Long-term target is 1 Fibonacci, short-term targets may be lower Fibonacci values. The pre-market shows a small potential recoil that can give a good Long entry point. Disclaimer: This article should not be considered as financial or investment advice. Trading digital assets involve risk and may resolve in the loss of your capital. Always be sure to understand the amount of risk involved and do your research before taking any trading/investment steps.
NASDAQ:CRSPLong
by randomname11
3
Re-visit my earlier call about CRSP/NTLA/EDITTo my followers; I made a call about these 3 companies couple of months back. Since then they have some good runs and the momentum seems to be getting even stronger. Check out this interview with Ms. Cathie Wood, founder and CEO of Ark Invest, about their technologies. www.youtube.com Personally I am holding some positions in these companies and looking for keep adding to it when time is right. Disclaimer, this is only for entertainment and education purposes and doesn't serve by any means as a buy or sell recommendation. Personally I hold both long term long positions and occasionally short term short position, for disclosure purpose.
NASDAQ:CRSP
by hanzhao311
1
Cup and Handle Patterns above PatternsAnother cup and handle has formed above the old cup and handle If you enjoy volatility this is a good one for you. This one may pull back again close to handle low of new cup and handle Remains to be seen Be patient and pick a good entry that works for you Stop to your tolerance or below handle low The last time this one reached long entry, iit did not hold on to the high. Deep pull back ensued and now CRSP seems to have energy again I see now a new all time high was just made but has pulled back again. If you like this stock, beware of volatility It appears Gene editing companies are hot as of late/TXG is another NV is high and short interest is mediocre but a bit higher than I like Be safe and be patient (o: Not a recommendation CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
NASDAQ:CRSPLong
by lauralea